Literature DB >> 33113586

Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas.

Hugo R de Jonge1, Maria C Ardelean2,3, Marcel J C Bijvelds1, Paola Vergani2.   

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) is an unusual ABC transporter. It acts as an anion-selective channel that drives osmotic fluid transport across many epithelia. In the gut, CFTR is crucial for maintaining fluid and acid-base homeostasis, and its activity is tightly controlled by multiple neuro-endocrine factors. However, microbial toxins can disrupt this intricate control mechanism and trigger protracted activation of CFTR. This results in the massive faecal water loss, metabolic acidosis and dehydration that characterize secretory diarrhoeas, a major cause of malnutrition and death of children under 5 years of age. Compounds that inhibit CFTR could improve emergency treatment of diarrhoeal disease. Drawing on recent structural and functional insight, we discuss how existing CFTR inhibitors function at the molecular and cellular level. We compare their mechanisms of action to those of inhibitors of related ABC transporters, revealing some unexpected features of drug action on CFTR. Although challenges remain, especially relating to the practical effectiveness of currently available CFTR inhibitors, we discuss how recent technological advances might help develop therapies to better address this important global health need.
© 2020 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Entities:  

Keywords:  CFTR pharmacology; G907 compound; cholera; cyclic AMP; cyclic GMP; enterocyte; glibenclamide; ion-channel gating; secretory diarrhea; zosuquidar

Mesh:

Substances:

Year:  2020        PMID: 33113586      PMCID: PMC7756540          DOI: 10.1002/1873-3468.13971

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   3.864


  166 in total

1.  Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion.

Authors:  Tonghui Ma; Jay R Thiagarajah; Hong Yang; Nitin D Sonawane; Chiara Folli; Luis J V Galietta; A S Verkman
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

2.  D-glucose acts via sodium/glucose cotransporter 1 to increase NHE3 in mouse jejunal brush border by a Na+/H+ exchange regulatory factor 2-dependent process.

Authors:  Rong Lin; Rakhilya Murtazina; Boyoung Cha; Molee Chakraborty; Rafiquel Sarker; Tian-E Chen; Zhihong Lin; Boris M Hogema; Hugo R de Jonge; Ursula Seidler; Jerrold R Turner; Xuhang Li; Olga Kovbasnjuk; Mark Donowitz
Journal:  Gastroenterology       Date:  2010-10-23       Impact factor: 22.682

3.  Conformational states of CFTR associated with channel gating: the role ATP binding and hydrolysis.

Authors:  K L Gunderson; R R Kopito
Journal:  Cell       Date:  1995-07-28       Impact factor: 41.582

4.  Molecular Structure of the Human CFTR Ion Channel.

Authors:  Fangyu Liu; Zhe Zhang; László Csanády; David C Gadsby; Jue Chen
Journal:  Cell       Date:  2017-03-23       Impact factor: 41.582

5.  Glibenclamide blockade of CFTR chloride channels.

Authors:  B D Schultz; A D DeRoos; C J Venglarik; A K Singh; R A Frizzell; R J Bridges
Journal:  Am J Physiol       Date:  1996-08

6.  Gating of cystic fibrosis transmembrane conductance regulator chloride channels by adenosine triphosphate hydrolysis. Quantitative analysis of a cyclic gating scheme.

Authors:  S Zeltwanger; F Wang; G T Wang; K D Gillis; T C Hwang
Journal:  J Gen Physiol       Date:  1999-04       Impact factor: 4.086

7.  P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site.

Authors:  I L Urbatsch; B Sankaran; J Weber; A E Senior
Journal:  J Biol Chem       Date:  1995-08-18       Impact factor: 5.157

Review 8.  Translating molecular physiology of intestinal transport into pharmacologic treatment of diarrhea: stimulation of Na+ absorption.

Authors:  Varsha Singh; Jianbo Yang; Tiane-e Chen; Nicholas C Zachos; Olga Kovbasnjuk; Alan S Verkman; Mark Donowitz
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-31       Impact factor: 11.382

9.  Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker.

Authors:  Alessandro Taddei; Chiara Folli; Olga Zegarra-Moran; Pascale Fanen; A S Verkman; Luis J V Galietta
Journal:  FEBS Lett       Date:  2004-01-30       Impact factor: 4.124

Review 10.  Inability to reduce morbidity of diarrhea by ORS: can we design a better therapy?

Authors:  Jane E Harrell; Sam X Cheng
Journal:  Pediatr Res       Date:  2018-01-03       Impact factor: 3.756

View more
  1 in total

1.  A Potential Treatment of Congenital Sodium Diarrhea in Patients With Activating GUCY2C Mutations.

Authors:  Anke H M van Vugt; Marcel J C Bijvelds; Hugo R de Jonge; Kelly F Meijsen; Tanja Restin; Manuel B Bryant; Antje Ballauff; Bart Koot; Thomas Müller; Roderick H J Houwen; Andreas R Janecke; Sabine Middendorp
Journal:  Clin Transl Gastroenterol       Date:  2021-11-18       Impact factor: 4.488

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.